To the Editor:

The term acute generalized exanthematous pustulosis (AGEP), coined by Beylot in 1980, refers to a rare form of cutaneous hypersensitivity characterized by multiple, small, sterile, nonfollicular pustules, appearing in groups on an area of erythematous skin. Although AGEP has sometimes been attributed to enterovirus infection or exposure to mercury, in 90% of cases it constitutes a drug-induced skin reaction. The antimicrobials, mainly the aminopenicillins, macrolides, and terbinafine figure among the most frequently implicated agents, although cases of AGEP have been reported associated with a long list of drugs including allopurinol, cyclooxygenase-2 inhibitors, omeprazole, and antiepileptic drugs. We present a case of AGEP that occurred in the context of the administration of diltiazem.

The patient was an 84-year-old woman with a history of long-standing systemic hypertension and atrial fibrillation. She was admitted to our hospital for decompensation of her heart failure. She denied any history of psoriasis. Her usual treatment included furosemide, verapamil, omeprazole, and acenocoumarol. At the time of admission, verapamil was changed to diltiazem (60 mg/d), but there were no other changes to her treatment. After 11 days in the hospital, she developed an erythematous rash on the trunk and abdomen and in the groin; numerous, nonfollicular, slightly confluent, pustular lesions then rapidly appeared on the rash (Figure 1). There was associated fever and general malaise, but no involvement of mucosal surfaces. The important finding in the blood tests was the presence of leukocytosis (20 400 cells/µL, with 87% neutrophils). Microbiological study was negative. Skin histology revealed multiple subcorneal pustules in different phases, formed of neutrophils, associated with a perivascular and periadnexal lymphocytic infiltrate (Figure 2). With the suspected diagnosis of diltiazem-related AGEP, treatment with that drug was interrupted. The fever resolved within 48 hours and the rash disappeared rapidly after a few days, associated with minimal desquamation.

From a clinical point of view, AGEP is characterized by the sudden onset of a pustular rash, predominantly affecting the trunk and skin folds, arising on an edematous area of diffuse erythema. The rash is usually associated with systemic manifestations (fever, leukocytosis, and renal failure), although life-threatening disease is very rare. Mucosal involvement is rare and is limited to the oral

Figure 1. Edematous, erythematous rash with multiple, small, partially confluent pustules: A, on the trunk and upper limbs, and B, on the lower limbs.
cavity. In 1991, Roujeau proposed a series of clinical and histological criteria to establish the diagnosis; these criteria include an acute onset of the rash and complete resolution in less than 15 days. The differential diagnosis includes generalized pustular psoriasis of von Zumbusch, and other severe forms of toxic skin disorders, such as exudative erythema multiforme major. Histologically, AGEP presents subcorneal spongiform pustules and collections of neutrophils, with papillary edema and focal necrosis of keratinocytes. The absence of eccrine involvement and of vacuolar changes at the dermoepidermal junction, common in exudative erythema multiforme major, is suggestive of AGEP. The differential diagnosis with generalized pustular psoriasis is more difficult, although the longer duration of the rash and the absence of a recent history of taking medication would suggest generalized pustular psoriasis. Although the etiology of AGEP is unknown, the in vitro demonstration of a specific lymphoproliferative response to drugs and the frequent positivity of skin patch tests in these patients would suggest a T-cell-mediated disorder, and the possibility of a common etiologic mechanism with psoriasis has been proposed.

Up to 5% of patients who receive treatment with diltiazem present some type of dose-dependent adverse reaction (headache, edema, atrioventricular blocks).

Table. Review of the 13 Cases of Acute Generalized Exanthematous Pustulosis Triggered by Diltiazem Reported in the Literature

<table>
<thead>
<tr>
<th>Patient</th>
<th>Author, Year (reference)</th>
<th>Age, y/ Sex</th>
<th>Dose of Diltiazem</th>
<th>Days Until Onset</th>
<th>Days Until Resolution</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Lambert et al, 1988</td>
<td>77/F</td>
<td>60 mg/8 h</td>
<td>10</td>
<td>5</td>
<td>Accidental re-exposure after 5 mo</td>
</tr>
<tr>
<td>2</td>
<td>Janier et al, 1993</td>
<td>83/F</td>
<td>NG</td>
<td>4</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>80/F</td>
<td>NG</td>
<td>15</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Sánchez et al, 1994</td>
<td>67/M</td>
<td>NG</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Wakelin and James, 1995</td>
<td>58/F</td>
<td>90 mg/12 h</td>
<td>10</td>
<td>7</td>
<td>Treatment with methotrexate was required. SPT positive</td>
</tr>
<tr>
<td>6</td>
<td>Blodgett et al, 1997</td>
<td>65/F</td>
<td>NG</td>
<td>14</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Vicente-Calleja et al, 1997</td>
<td>71/F</td>
<td>100 mg/12 h</td>
<td>21</td>
<td>Very few</td>
<td>SPT positive 2 mo after resolution</td>
</tr>
<tr>
<td>8</td>
<td>Knowles et al, 1998</td>
<td>48/M</td>
<td>120 mg/24 h</td>
<td>10</td>
<td>12</td>
<td>Treatment with corticosteroids was required</td>
</tr>
<tr>
<td>9</td>
<td>Jan et al, 1998</td>
<td>82/F</td>
<td>200 mg</td>
<td>24 h</td>
<td>NG</td>
<td>Previous episodes of pustular rash after diltiazem. SPT positive</td>
</tr>
<tr>
<td>10</td>
<td>Arroyo et al, 2002</td>
<td>47/F</td>
<td>NG</td>
<td>NG</td>
<td>NG</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Girardi et al, 2005</td>
<td>72/F</td>
<td>NG</td>
<td>NG</td>
<td>NG</td>
<td>Correlation between SPT and the in vitro lymphoproliferative response</td>
</tr>
<tr>
<td>12</td>
<td>Gesierich et al, 2006</td>
<td>60/F</td>
<td>NG</td>
<td>14</td>
<td>Very few</td>
<td>SPT positive 3 mo after resolution</td>
</tr>
<tr>
<td>13</td>
<td>Present case, 2008</td>
<td>84/F</td>
<td>60 mg/12 h</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations; F; female; M, male; NG: not given; SPT: skin patch test.
Skin toxicity can present with a wide spectrum of manifestations: pruritus, urticaria, a maculopapular or, more rarely, petechial rash, photosensitivity, exudative erythema multiforme major, toxic epidermal necrolysis, and vasculitis. Exposure to diltiazem is a rare but well-documented cause of AGEP. The Table summarizes the clinical features and course of the 13 cases reported up to now in the literature in English and Spanish, including the present case (search in PubMed using the key words: “diltiazem” or “calcium-channel blocker” and “pustulosis” or “AGEP”). The review of these cases shows a marked female predominance (male to female ratio, 2 to 11). The delay in the onset of symptoms varies between 24 hours and 3 weeks after starting treatment with diltiazem (mean [SD], 11.4 [5.5] days). After withdrawal of treatment, complete resolution of the rash occurs in 7.3 (2.4) days. Those cases in which the accidental rechallenge was documented provide the most conclusive evidence in favor of the implication of diltiazem as a trigger of the condition. The use of patch tests constitutes a valid option for confirming this association, as positive results have been found in all cases in which those tests were performed. In conclusion, the calcium channel blockers and, in particular, diltiazem, must be considered to be potential triggers of AGEP. Positive skin patch testing will confirm the diagnosis in cases of atypical clinical presentation.

Correspondence:
Mario Fernández Ruiz
Secretaría del Servicio de Medicina Interna (planta 13)
Hospital Universitario 12 de Octubre
Avda. de Córdoba, s/n
28041 Madrid, Spain
mario_fdezruiz@yahoo.es

Conflicts of Interest
The authors declare no conflicts of interest.

References

Chronic Painless Dactylitis as the Initial Finding in Disseminated Lung Adenocarcinoma

A. Martorell-Calatayud, B. Liombart-Cussac, C. Requena-Caballero, and C. Guillén-Barona
Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain

To the Editor:
Cutaneous metastases secondary to primary visceral tumor are uncommon events, occurring in 0.7% to 9% of cases. They usually appear in patients previously diagnosed with a primary tumor. We present the case of a patient who developed chronic painless dactylitis that was histologically compatible with a previously unknown underlying metastatic lung adenocarcinoma.

The patient was a 56-year-old woman, a nonsmoker with hypertension, who was admitted for evaluation...